Elpida Insights

Not All Violations Were Born Equal

Elpida team | Fri 27 2026

Most tools flag everything. We score what the FDA and FTC actually enforce, using real warning-letter patterns.

Your back office is AI-driven. Your front door is defenseless.

Elpida team | Fri 27 2026

Healthcare consulting agencies are helping partners move fast, but “move fast and fix it later” is a financial death sentence in 2026. While the industry obsesses over documentation efficiency, the FDA and global regulators have moved their own AI into high gear.

The Quiet MLR Revolution

Gal Levenhaim, Elpida CEO | Feb 15 2026

We are witnessing a quiet revolution in healthcare. While the industry debates the safety of AI, the FDA has already operationalized it.
Federal authorities are now powered by agentic AI, turning traditional audits into 24/7 digital enforcement. This creates a machine-speed surveillance gap that manual workflows can no longer bridge.

Compliance AI – The Future

Ben-Ari Kutai, Elpida CTO | Feb 15 2026

The future of AI compliance isn’t a smarter model, it’s stronger organizational memory. Elpida captures your legal team’s decisions as reusable skills, building a compliance layer that gets smarter over time and safeguards every claim before it goes live.

The Elpida Shield In Action – The Crash – Test Case 02

Elpida | Feb 15 2026

A brain-wellness startup’s “move fast” marketing triggered an FDA Warning Letter and an 85% revenue drop. Elpida’s Shield would have blocked risky claims at draft stage, enabling zero-risk scaling, protected valuation, and total confidence under AI surveillance.

The Elpida Shield In Action – Test Case 01

Elpida | 11.08.26

A brain-wellness brand pushed “doctor-recommended” claims and got flagged, triggering a marketing shutdown and a steep revenue hit. Elpida would have blocked risky claims at draft stage and kept growth moving s

Don’t Bring a Knife to a Gunfight

Elpida | Feb 15 2026

AI-driven FDA surveillance is accelerating enforcement, and human-only MLR is now a strategic liability. Elpida’s Shield and Catalyst create a bi-directional compliance perimeter that removes blind spots and compresses review cycles from months to minutes so you can scale with confidence and protect valuation.

The Wake Up Call

Elpida | 11.08.26

With the FDA using AI like ELSA to scan for violations 24/7, manual MLR can’t keep up. Elpida’s bi-directional compliance infrastructure protects you from the outside in by scanning every asset against changing regulations, and from the inside out by validating every edit in real time so your brand stays continuously audit-ready.